Search results
Results from the WOW.Com Content Network
Current Cancer Drug Targets is a peer-reviewed medical journal published by Bentham Science Publishers. The editor-in-chief is Ruiwen Zhang ( UH Drug Discovery Institute). The journal covers research on contemporary molecular drug targets involved in cancer , including medicinal chemistry , pharmacology , molecular biology , genomics , and ...
Target validation normally requires the determination that the target is expressed in the disease-relevant cells/tissues, [6] it can be directly modulated by a drug or drug-like molecule with adequate potency in biochemical assay, [7] and that target modulation in cell and/or animal models ameliorates the relevant disease phenotype. [8]
Journal of Drug Targeting is a peer-reviewed medical journal published by Informa that covers research on all aspects of drug delivery and drug targeting for molecular and macromolecular drugs. The editor in chief is Saghir Akhtar (College of Medicine, Qatar University ).
Drug Target Insights is a peer-reviewed open access academic journal focusing on drug treatment targets and clinical therapeutics. The journal was founded in 2006 by Monica Milani and is currently edited by Giulio Zuanetti .
Drug Discovery Today is a monthly peer-reviewed scientific journal that is published by Elsevier.It was established in 1996 and publishes reviews on all aspects of preclinical drug discovery from target identification and validation through hit identification, lead identification and optimisation, to candidate selection.
Current Drug Metabolism is a peer-reviewed medical journal covering the study of drug metabolism. It was established in 2000 and is published 10 times per year by Bentham Science Publishers. The editor-in-chief is Ming Hu [2] (University of Houston). According to the Journal Citation Reports, the journal has a 2019 impact factor of 2.960. [3]
This list of pharmaceutical compound number prefixes provides codes used by individual pharmaceutical companies when naming their pharmaceutical drug candidates. . Pharmaceutical companies generally produce large numbers of compounds in the research phase for which it is impractical to use often long and cumbersome systematic chemical names, and for which the effort to generate nonproprietary ...
Germline mutations in drug targets can also influence response to medications, though this is an emerging subfield within pharmacogenomics. One well-established gene-drug interaction involving a germline mutation to a drug target is warfarin (Coumadin) and VKORC1 , which codes for vitamin K epoxide reductase (VKOR) .